ADMA - ADMA Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.99
+0.03 (+0.60%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.96
Open4.94
Bid4.79 x 2200
Ask0.00 x 900
Day's Range4.93 - 5.10
52 Week Range2.01 - 5.70
Volume157,754
Avg. Volume181,562
Market Cap225.021M
Beta2.72
PE Ratio (TTM)N/A
EPS (TTM)-1.77
Earnings DateMay 10, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.88
Trade prices are not sourced from all markets
  • Benzinga8 days ago

    Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 12) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...

  • GlobeNewswire9 days ago

    ADMA Biologics Announces Closing of $40M Public Offering

    RAMSEY, N.J. and BOCA RATON, Fla., June 12, 2018-- ADMA Biologics, Inc. announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a ...

  • GlobeNewswire13 days ago

    ADMA Biologics Announces Pricing of Public Offering of Common Stock

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today the pricing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share, resulting in gross proceeds of approximately $40.0 million before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on June 12, 2018, subject to the satisfaction of customary closing conditions.  The Company has also granted the underwriters a 30-day option to purchase up to 1,255,230 additional shares of common stock at the public offering price before deducting underwriting discounts and commissions. ADMA intends to use the net proceeds from this offering (i) for continued remediation and ongoing improvement and enhancements at its plasma fractionation facility located in Boca Raton, FL, (ii) to submit the Prior Approval Supplement for, and relaunch of, Bivigam®, (iii) to resubmit the Biologics License Application for its lead pipeline product candidate, RI-002, (iv) in connection with U.S. Food and Drug Administration approval of its third plasma collection facility, and (v) for general corporate purposes and other capital expenditures.

  • GlobeNewswire14 days ago

    ADMA Biologics Announces Proposed Public Offering of Common Stock

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today that it has commenced an underwritten public offering of its common stock.  The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering.  The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Raymond James & Associates, Inc. is acting as the sole book-running manager of the proposed offering.

  • Zacks Small Cap Research17 days ago

    ADMA: Biotest Share Retirement Good for Shareholders

    ADMA Biologics, Inc. (ADMA) filed its 10-K and press release for its first quarter 2018 financial results on May 14, 2018. The highlights year to date have included the release of the first commercial batch of Nabi-HB to be manufactured under its ownership, the retirement of 8.6 million shares issued to Biotest and the grant of a patent for treating respiratory infections related to RI-002. The facility has been inspection-ready by the turn of the year and we await the arrival of the FDA inspection team.

  • Who Owns Most Of ADMA Biologics Inc (NASDAQ:ADMA)?
    Simply Wall St.last month

    Who Owns Most Of ADMA Biologics Inc (NASDAQ:ADMA)?

    Today, I will be analyzing ADMA Biologics Inc’s (NASDAQ:ADMA) recent ownership structure, an important but not-so-popular subject among individual investors. A company’s ownership structure is often linked to its shareRead More...

  • ACCESSWIRElast month

    Blog Exposure - ADMA Biologics Received US Patent for Treating Respiratory Infections

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMA as the Company's latest news hit the wire. On May 16, 2018, the New Jersey-based biopharmaceutical Company announced that the United States Patent and Trademark Office has issued to ADMA US Patent No. 9,969,793 covering methods of treating respiratory infections. Active-Investors.com is currently working on the research report for Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), which also belongs to the Healthcare sector as the Company ADMA Biologics.

  • GlobeNewswirelast month

    ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 9,969,793 covering methods of treating respiratory infections. The newly issued patent encompasses methods of treating upper and lower respiratory infections, including those caused by Respiratory Syncytial Virus (“RSV”), other viruses, as well as bacteria utilizing ADMA’s investigational drug RI-002 that contains elevated, neutralizing antibody titers to RSV as well as elevated antibody titers to other respiratory pathogens, such as influenza virus, coronavirus, parainfluenza virus, and metapneumovirus. “The addition of this patent to ADMA’s immunoglobulin portfolio provides unique coverage for the therapeutic treatment of respiratory infections using our investigational drug RI-002,” stated Adam Grossman, President and CEO of ADMA.

  • Associated Presslast month

    Adma Biologics: 1Q Earnings Snapshot

    The Ramsey, New Jersey-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring costs, came to 35 cents per share. The infectious disease drug developer posted revenue ...

  • GlobeNewswirelast month

    ADMA Biologics Reports First Quarter 2018 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., May 14, 2018-- ADMA Biologics, Inc., today announced its financial results for the quarter ended March 31, 2018 and provided an update on its operations and corporate ...

  • GlobeNewswirelast month

    ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest

    RAMSEY, N.J. and BOCA RATON, Fla., May 14, 2018-- ADMA Biologics, Inc. announced today that it has negotiated the receipt and immediate retirement of approximately 8.6 million shares of its non-voting ...

  • Will ADMA Biologics Inc’s (NASDAQ:ADMA) Earnings Grow In The Next Couple Of Years?
    Simply Wall St.last month

    Will ADMA Biologics Inc’s (NASDAQ:ADMA) Earnings Grow In The Next Couple Of Years?

    The most recent earnings announcement ADMA Biologics Inc’s (NASDAQ:ADMA) released in December 2017 revealed that losses became smaller relative to the prrior year’s level as a result of recent tailwindsRead More...

  • GlobeNewswire2 months ago

    ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership

    RAMSEY, N.J. and BOCA RATON, Fla., April 24, 2018-- ADMA Biologics, Inc., today announced that it has successfully completed the manufacturing, release and has made commercial sales of its first batch ...

  • ADMA Biologics Inc (NASDAQ:ADMA): Should The Recent Earnings Drop Worry You?
    Simply Wall St.3 months ago

    ADMA Biologics Inc (NASDAQ:ADMA): Should The Recent Earnings Drop Worry You?

    Assessing ADMA Biologics Inc’s (NASDAQ:ADMA) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, whichRead More...

  • When Will ADMA Biologics Inc (NASDAQ:ADMA) Turn A Profit?
    Simply Wall St.3 months ago

    When Will ADMA Biologics Inc (NASDAQ:ADMA) Turn A Profit?

    ADMA Biologics Inc’s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-based biologics for the treatment of immune deficiencies and infectious diseases. On 31 December 2017,Read More...

  • Does ADMA Biologics Inc’s (NASDAQ:ADMA) CEO Salary Compared Well With Others?
    Simply Wall St.5 months ago

    Does ADMA Biologics Inc’s (NASDAQ:ADMA) CEO Salary Compared Well With Others?

    Leading ADMA Biologics Inc (NASDAQ:ADMA) as the CEO, Adam Grossman took the company to a valuation of $178.55M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Does ADMA Biologics Inc’s (NASDAQ:ADMA) Past Performance Indicate A Weaker Future?
    Simply Wall St.6 months ago

    Does ADMA Biologics Inc’s (NASDAQ:ADMA) Past Performance Indicate A Weaker Future?

    Understanding ADMA Biologics Inc’s (NASDAQ:ADMA) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...

  • ACCESSWIRE6 months ago

    Wired News – ADMA Files Biologics License Application for Its Third Plasma Collection Center

    Stock Monitor: Can-Fite BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on ADMA Biologics, Inc. (NASDAQ: ADMA ) ("ADMA"), ...

  • Capital Cube7 months ago

    ETFs with exposure to ADMA Biologics, Inc. : November 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?
    Simply Wall St.7 months ago

    ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?

    For ADMA Biologics Inc’s (NASDAQ:ADMA) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...

  • Zacks Small Cap Research7 months ago

    ADMA: Third Quarter 2017 Financial Results and Corporate Update

    By John Vandermosten, CFA NASDAQ:ADMA ADMA Biologics, Inc. (NASDAQ: ADMA) experienced its first full quarter merged with the Biotest Therapy Business Unit (BTBU) and reported 3Q:17 results on November ...